Company | Date | Price Target | Rating | Analyst |
---|---|---|---|---|
6/3/2024 | $142.00 | Buy | Jefferies | |
4/8/2024 | $117.00 | Buy | Craig Hallum | |
2/20/2024 | $68.00 → $85.00 | Strong Buy → Outperform | Raymond James | |
12/29/2023 | $75.00 → $85.00 | Buy | BTIG Research | |
12/14/2023 | $70.00 | Buy | Guggenheim | |
12/13/2023 | $70.00 | Outperform | Wolfe Research | |
11/13/2023 | $68.00 | Outperform → Strong Buy | Raymond James | |
9/28/2023 | $48.00 | Mkt Perform | Bernstein |
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the second quarter ended June 30, 2024. Recent Strategic and Financial Highlights Generated total revenues of $413.4 million in the second quarter of 2024, compared to $261.4 million in the second quarter of 2023, an increase of 58.1%. Product revenues grew 59.3% over the same period. Generated a gross margin of 58.8% in the second quarter of 2024, compared to a gross margin of 45.2% in the second quarter of 2023. Processed approximately 760,300 tests in the second quarter of 2024, compared to approximately 617,200 tests in the second quarter of 2023, an incr
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended June 30, 2024, after the market close on Aug. 8, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information: Event: Natera's Second Quarter 2024 Financial Results Date: Thursday, Aug. 8, 2024 Time: 1:30 p.m. PT (4:30 p.m. ET) Live Dial-In: 1-888-596-4144 (Domestic) 1-646-968-2525 (International) Conference ID: 7684785 Webcast: https://events.q4inc.com/attendee/455235752 A web
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the first quarter ended March 31, 2024. Recent Strategic and Financial Highlights Achieved positive cash flow of approximately $3.0 million1 in the first quarter of 2024. Generated total revenues of $367.7 million in the first quarter of 2024, compared to $241.8 million in the first quarter of 2023, an increase of 52.1%. Product revenues grew 53.4% over the same period. Generated gross margins of 56.7% in the first quarter of 2024, compared to gross margins of 38.7% in the first quarter of 2023. Processed approximately 735,800 tests in the first quarter of
10-Q - Natera, Inc. (0001604821) (Filer)
8-K - Natera, Inc. (0001604821) (Filer)
8-K - Natera, Inc. (0001604821) (Filer)
4 - Natera, Inc. (0001604821) (Issuer)
4 - Natera, Inc. (0001604821) (Issuer)
4 - Natera, Inc. (0001604821) (Issuer)
SC 13G/A - Natera, Inc. (0001604821) (Subject)
SC 13G/A - Natera, Inc. (0001604821) (Subject)
SC 13G/A - Invitae Corp (0001501134) (Subject)
Jefferies resumed coverage of Natera with a rating of Buy and set a new price target of $142.00
Craig Hallum resumed coverage of Natera with a rating of Buy and set a new price target of $117.00
Raymond James downgraded Natera from Strong Buy to Outperform and set a new price target of $85.00 from $68.00 previously
Signatera now has >85 peer-reviewed publications with clinical validation across multiple cancer types and indications Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today announced the simultaneous publication of three peer-reviewed papers, crossing a milestone of more than 85 peer-reviewed publications on Signatera. This includes: Groundbreaking colorectal cancer (CRC) data from the GALAXY arm of the ongoing CIRCULATE-Japan trial, published today in Nature Medicine, and also available in Poster Presentation #553P at the 2024 Congress of the European Society for Medical Oncology (ESMO) in Barcelona, Spain. Additional CRC data from GALAXY, published
Shows nearly 10x advantage in overall survival at 36 months based on ctDNA status and affirms Signatera's ability to predict chemotherapy benefit Shows a 50% reduction in risk of death for Signatera-positive patients when treated with ACT Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, announced that new data from the GALAXY arm of the ongoing CIRCULATE-Japan trial was released today at the 2024 Congress of the European Society for Medical Oncology (ESMO) in Barcelona, Spain. GALAXY is one of the largest and most comprehensive prospective studies of circulating tumor DNA (ctDNA) testing in resectable colorectal cancer (CRC). This latest analysis, which w
Presentations include abstracts from the GALAXY arm of the CIRCULATE-Japan trial, along with new data in Breast Cancer and Squamous Cell Carcinoma of the Head and Neck Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today announced it will present new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, at the 2024 European Society for Medical Oncology (ESMO) Congress taking place Sept. 13-16 in Barcelona, Spain. Natera and its collaborators will present a total of nine abstracts, including five poster presentations from the GALAXY observational arm of the CIRCULATE-Japan trial, one of the largest and most comprehe
Natera's (NYSE:NTRA) short percent of float has risen 15.19% since its last report. The company recently reported that it has 6.38 million shares sold short, which is 5.46% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.14 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest is imp
Natera (NASDAQ:NTRA) has outperformed the market over the past 5 years by 18.07% on an annualized basis producing an average annual return of 31.07%. Currently, Natera has a market capitalization of $12.47 billion. Buying $100 In NTRA: If an investor had bought $100 of NTRA stock 5 years ago, it would be worth $386.36 today based on a price of $101.57 for NTRA at the time of writing. Natera's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and reviewed by
Natera (NASDAQ:NTRA) has outperformed the market over the past 5 years by 19.94% on an annualized basis producing an average annual return of 33.11%. Currently, Natera has a market capitalization of $13.71 billion. Buying $1000 In NTRA: If an investor had bought $1000 of NTRA stock 5 years ago, it would be worth $4,293.85 today based on a price of $111.64 for NTRA at the time of writing. Natera's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and reviewe
Pioneering Pharmacogenomics Platform Joins Portfolio of Complementary Precision Medicine Workflow Solutions Aranscia, a global provider of diagnostics software, services, and testing solutions, and Invitae Corporation, a leading medical genetics company, today announced that Aranscia has acquired select assets of the YouScript personalized medication management platform from Invitae Corporation in an all-cash transaction. YouScript is a widely recognized leader in providing actionable, real-time medication risk and pharmacogenomics (PGx) insights that enable healthcare providers and organizations to build, deliver, and scale comprehensive personalized medication management programs. YouSc
SAN FRANCISCO, Sept. 25, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced the appointment of finance veteran Ana Schrank as the Company's chief financial officer (CFO), effective October 2. Robert Dickey, who has been the Company's interim CFO since August 2023, will transition to a consulting role for the Company and will work closely with Ms. Schrank and the leadership team to ensure a smooth transition. www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the qu
– Invitae adds chief commercial officer to leadership team; Innovative leader to help expand market share and drive revenue growth – SAN FRANCISCO, Aug. 28, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced that it has appointed Robert (Rob) Guigley as its chief commercial officer, effective September 5, 2023. Mr. Guigley brings to the role more than 20 years of commercial experience spanning biotechnology, pharmaceuticals, diagnostics and genetic testing. He will develop and implement Invitae's commercial strategy with a focus on driving profitable revenue growth, expanding the market, improving reimbursement levels and enhancing the service of